Geode Capital Management LLC increased its stake in shares of Zogenix, Inc. (NASDAQ:ZGNX) by 44.8% during the 4th quarter, HoldingsChannel reports. The fund owned 307,105 shares of the company’s stock after purchasing an additional 95,042 shares during the quarter. Geode Capital Management LLC’s holdings in Zogenix were worth $12,299,000 as of its most recent SEC filing.
A number of other large investors also recently made changes to their positions in the stock. Carillon Tower Advisers Inc. acquired a new stake in Zogenix during the 4th quarter worth $27,776,000. American International Group Inc. raised its stake in Zogenix by 38.7% during the 4th quarter. American International Group Inc. now owns 23,057 shares of the company’s stock worth $923,000 after acquiring an additional 6,434 shares in the last quarter. Vivo Capital LLC acquired a new stake in Zogenix during the 4th quarter worth $4,205,000. Virtu Financial LLC acquired a new stake in Zogenix during the 4th quarter worth $683,000. Finally, BlackRock Inc. raised its stake in Zogenix by 30.6% during the 4th quarter. BlackRock Inc. now owns 2,656,444 shares of the company’s stock worth $106,389,000 after acquiring an additional 622,668 shares in the last quarter.
NASDAQ ZGNX opened at $36.45 on Friday. The firm has a market capitalization of $1,339.27, a price-to-earnings ratio of -9.07 and a beta of 1.68. Zogenix, Inc. has a one year low of $10.05 and a one year high of $45.85.
Zogenix (NASDAQ:ZGNX) last posted its quarterly earnings data on Tuesday, March 6th. The company reported ($1.14) EPS for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.17). During the same quarter in the prior year, the business posted ($0.95) EPS. equities research analysts anticipate that Zogenix, Inc. will post -3.12 EPS for the current year.
Several brokerages recently commented on ZGNX. ValuEngine upgraded shares of Zogenix from a “hold” rating to a “buy” rating in a research note on Monday, April 2nd. Zacks Investment Research upgraded shares of Zogenix from a “hold” rating to a “buy” rating and set a $50.00 price target on the stock in a research note on Thursday, March 15th. Leerink Swann reiterated an “outperform” rating on shares of Zogenix in a research note on Sunday, March 4th. Mizuho reiterated a “buy” rating and set a $51.00 price target on shares of Zogenix in a research note on Wednesday, March 7th. Finally, BidaskClub upgraded shares of Zogenix from a “hold” rating to a “buy” rating in a research note on Saturday, February 10th. Eight equities research analysts have rated the stock with a buy rating, The stock currently has a consensus rating of “Buy” and a consensus price target of $53.20.
In other Zogenix news, Director Roger Hawley sold 35,000 shares of Zogenix stock in a transaction on Tuesday, March 13th. The shares were sold at an average price of $44.71, for a total value of $1,564,850.00. The transaction was disclosed in a document filed with the SEC, which is available through this link. Insiders own 5.00% of the company’s stock.
TRADEMARK VIOLATION WARNING: This piece was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece on another domain, it was stolen and reposted in violation of US and international copyright and trademark law. The original version of this piece can be accessed at https://www.dispatchtribunal.com/2018/04/07/geode-capital-management-llc-has-12-30-million-stake-in-zogenix-inc-zgnx.html.
Zogenix, Inc is a pharmaceutical company engaged in developing and commercializing central nervous system (CNS) therapies that address specific clinical needs for people living with orphan and other CNS disorders. Its primary area of therapeutic focus is epilepsy and related seizure disorders. Its lead product candidate, ZX008, is a low-dose fenfluramine for the treatment of seizures associated with Dravet syndrome.
Want to see what other hedge funds are holding ZGNX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zogenix, Inc. (NASDAQ:ZGNX).
Receive News & Ratings for Zogenix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zogenix and related companies with MarketBeat.com's FREE daily email newsletter.